Lipid [lipd]
Altered [ftcn]
Efficacy [qlco]
Safety [hcpp]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Extended Release [bodm]
Niacin [orch, phsu, vita]
Patients [podg]
Type [qlco]
Type IIb Hyperlipidemia [dsyn]
objectives [inpr]
thi [euka]
Study [mnob]
Evaluated [ftcn]
Safety [hcpp]
Lipid [lipd]
Altered [ftcn]
Efficacy [qlco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Extended Release [bodm]
Niacin [orch, phsu, vita]
Patients [podg]
Type [qlco]
Hyperlipidaemia [dsyn]
Background [cnce]
Current [tmco]
Guidelines [inpr]
recommend [idcn]
consideration [fndg]
Combination Drug Therapy [topp]
Optimal [qlco]
Low Density Lipoprotein Cholesterol [bacs, strd]
lowering [spco]
Broad [spco]
Lipid [lipd]
Altered [ftcn]
effects [qlco]
treating [topp]
Patients [podg]
High Risk [qlco]
atherosclerotic [ftcn]
cardiovascular events [fndg]
Methods [inpr]
randomized [resa]
Double-Blind Study [resa]
Type [qlco]
Patients [podg]
randomized [resa]
treatment [ftcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
mg day [qnco]
Niacin [orch, phsu, vita]
Titrate [hlca]
g/day [qnco]
Niacin [orch, phsu, vita]
Titrate [hlca]
g/day [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
mg day [qnco]
baseline [bodm]
Primary [qlco]
secondary [neop]
variables [qlco]
Assessed [acty]
Modified [ftcn]
intent [qlco]
TREAT [ftcn]
Population [qnco]
Result [ftcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Niacin [orch, phsu, vita]
Result [ftcn]
reductions [npop]
Non [ftcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
Apolipoprotein B [aapp, bacs]
lipid lipoprotein [aapp, lipd]
Ratios [qnco]
Compared [acty]
Agent [chvf]
Alone [qnco]
P NOS [aapp, imft]
Combination [qlco]
Increased [qnco]
Levels [qlco]
Apolipoprotein A [aapp, bacs]
High Density Lipoprotein Cholesterol [bacs, lipd]
EZETIMIBE/SIMVASTATIN [orch, phsu]
P NOS [aapp, imft]
Reduced [qlco]
High sensitivity [lbpr]
C-reactive protein level [lbpr]
Niacin [orch, phsu, vita]
P NOS [aapp, imft]
Percentage [qnco]
Patients [podg]
Discontinued [fndg]
Study [mnob]
Niacin [orch, phsu, vita]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Niacin [orch, phsu, vita]
Group [idcn]
Compared [acty]
EZETIMIBE/SIMVASTATIN [orch, phsu]
P NOS [aapp, imft]
Clinical [qlco]
Adverse Experience [fndg]
Flushing [sosy]
Incidences [qnco]
Clinical [qlco]
Laboratory [mnob, orgt]
Adverse Experience [fndg]
Liver [bpoc]
Muscle [tisu]
gastrointestinal [spco]
Similar [qlco]
Group [idcn]
Conclusions [idcn]
Combination [qlco]
treatment [ftcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Plus [qlco]
Niacin [orch, phsu, vita]
Show [inpr]
Superior [spco]
Lipid [lipd]
Altered [ftcn]
Efficacy [qlco]
Compared [acty]
Niacin [orch, phsu, vita]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Type [qlco]
Hyperlipidaemia [dsyn]
Patients [podg]
Well [qlco]
Niacin [orch, phsu, vita]
Associated [qlco]
Flushing [sosy]
This [euka]
Combination [qlco]
effective [qlco]
Broad [spco]
Lipid [lipd]
Altered [ftcn]
therapy [ftcn]
Improvement [cnce]
Lipid [lipd]
effects [qlco]
Patients [podg]
To [qlco]
Evaluate [ftcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Niacin [orch, phsu, vita]
Extended Release Tablet [bodm]
Patients [podg]
high cholesterol [fndg]
